{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T09:46:43Z","timestamp":1764841603820,"version":"build-2065373602"},"reference-count":109,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.hoc.2008.07.013","type":"journal-article","created":{"date-parts":[[2008,10,28]],"date-time":"2008-10-28T09:21:01Z","timestamp":1225185661000},"page":"863-882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Follicular Lymphoma: Clinical Features and Treatment"],"prefix":"10.1016","volume":"22","author":[{"given":"Daryl","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra J.","family":"Horning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2008.07.013_bib1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma classification project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib2","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin's lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2008.07.013_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.1983.1.1.11","article-title":"Histologic conversion in the non-Hodgkin's lymphomas","volume":"1","author":"Acker","year":"1983","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/1097-0142(19830801)52:3<393::AID-CNCR2820520302>3.0.CO;2-M","article-title":"An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute","volume":"52","author":"Garvin","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2008.07.013_bib5","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood.V59.2.258.258","article-title":"Histologic progression in non-Hodgkin's lymphoma","volume":"59","author":"Hubbard","year":"1982","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.hoc.2008.07.013_bib6","first-page":"S98","article-title":"Pediatric follicular lymphomas, marginal zone lymphomas, and marginal zone hyperplasia","volume":"122","author":"Swerdlow","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.hoc.2008.07.013_bib7","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/annonc\/mdg168","article-title":"Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review","volume":"14","author":"Damaj","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib8","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.1994.12.7.1343","article-title":"Applicability of the international index for aggressive lymphomas to patients with low-grade lymphoma","volume":"12","author":"L\u00f3pez-Guillermo","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib9","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular Lymphoma International Prognostic Index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib10","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib11","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib12","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib13","article-title":"Revalidation of FLIPI in patients with follicular lymphoma (FL) registered in the F2 study and treated upfront with immunochemotherapy","volume":"25","author":"Federico","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib14","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib15","doi-asserted-by":"crossref","first-page":"792A","DOI":"10.1182\/blood.V110.11.792.792","article-title":"Final analysis of the GELA-GOELAMS FL2000 study with a 5-year follow-up","volume":"110","author":"Salles","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib16","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib17","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2002-07-2298","article-title":"A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival","volume":"101","author":"Hans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/gcc.1103","article-title":"Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18)","volume":"30","author":"Horsman","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.hoc.2008.07.013_bib19","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2008.07.013_bib20","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","article-title":"Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)","volume":"106","author":"Farinha","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib21","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2006.06.4642","article-title":"Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib22","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1200\/JCO.2006.06.1648","article-title":"Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma","volume":"25","author":"Glas","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib23","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1182\/blood-2006-11-058040","article-title":"Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival","volume":"109","author":"Cerhan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center","volume":"13","author":"Johnson","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib25","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin's lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib26","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib27","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib28","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib29","doi-asserted-by":"crossref","first-page":"3428A","DOI":"10.1182\/blood.V110.11.3428.3428","article-title":"Survival in follicular lymphoma: the Stanford experience, 1960\u20132003","volume":"110","author":"Tan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib30","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1200\/JCO.1995.13.7.1726","article-title":"Long-term survival after histologic transformation of low-grade follicular lymphoma","volume":"13","author":"Yuen","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib31","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib32","article-title":"Improved prognosis after histologic transformation of follicular lymphoma: the Stanford experience 1960\u20132003. Programs and abstracts of the 10th International Conference on Malignant Lymphoma","author":"Tan","year":"2008","journal-title":"Lugano"},{"key":"10.1016\/j.hoc.2008.07.013_bib33","first-page":"790","article-title":"Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma","volume":"110","author":"Al-Tourah","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.hoc.2008.07.013_bib34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/0003-4819-90-1-10","article-title":"No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types","volume":"90","author":"Portlock","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hoc.2008.07.013_bib35","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2008.07.013_bib36","first-page":"11","article-title":"The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment","volume":"25","author":"Young","year":"1988","journal-title":"Semin Hematol"},{"key":"10.1016\/j.hoc.2008.07.013_bib37","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/1097-0142(197603)37:3<1275::AID-CNCR2820370307>3.0.CO;2-M","article-title":"Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non-Hodgkin's lymphomas","volume":"37","author":"Portlock","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2008.07.013_bib38","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival","volume":"4","author":"Gallagher","year":"1986","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2008.07.013_bib39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/annonc\/5.suppl_2.S67","article-title":"Chlorambucil\/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden","volume":"5","author":"Kimby","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2003.05.128","article-title":"Prolonged single agent versus combination chemotherapy in indolent follicular lymphomas. A study of the Cancer and Leukemia Group B","volume":"21","author":"Peterson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib41","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.1996.14.2.514","article-title":"Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"14","author":"Solal-C\u00e9ligny","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib42","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.1996.14.4.1262","article-title":"Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma","volume":"14","author":"McLaughlin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib43","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1200\/JCO.2003.09.047","article-title":"Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501","volume":"21","author":"Velasquez","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib44","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib45","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.2005.03.7952","article-title":"Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma","volume":"24","author":"Hagenbeek","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib46","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib47","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib48","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib50","first-page":"486","article-title":"Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up (F\/Up) of 7 years","volume":"108","author":"Colombat","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.hoc.2008.07.013_bib51","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib52","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3816\/CLM.2006.n.024","article-title":"Eastern Cooperative Oncology Group 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT)","volume":"6","author":"Kahl","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.hoc.2008.07.013_bib53","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib54","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V108.11.481.481","article-title":"MabThera (rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkins lymphoma","volume":"108","author":"Marcus","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib55","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1182\/blood.V106.11.349.349","article-title":"Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial","volume":"106","author":"Hochster","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib56","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib57","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib58","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib59","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib60","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2000.18.6.1316","article-title":"Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed\/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"18","author":"Vose","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib61","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib62","first-page":"2184A","article-title":"Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: results of a multi-center phase II study","volume":"96","author":"Horning","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib63","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2008.07.013_bib64","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2003-01-0287","article-title":"A phase 2 trial of CHOP chemotherapy followed by tositumomab\/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911","volume":"102","author":"Press","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib65","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1200\/JCO.2005.14.803","article-title":"Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib66","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood.V110.11.643.643","article-title":"90Y-Ibritumomab tiuxetan (Zevalin(R)) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma: first results of the international randomized phase 3 First-Line Indolent Trial (FIT) in 414 patients","volume":"110","author":"Hagenbeek","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib67","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V88.7.2780.bloodjournal8872780","article-title":"High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission","volume":"88","author":"Freedman","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib68","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.V97.2.404","article-title":"High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial","volume":"97","author":"Horning","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib69","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.bmt.1702631","article-title":"Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study","volume":"26","author":"Colombat","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2008.07.013_bib70","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2004.10.054","article-title":"Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib71","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib72","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib73","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib74","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V89.9.3129","article-title":"Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma\u2014long-term results of a clinical trial","volume":"89","author":"Hsu","year":"1997","journal-title":"Blood"},{"journal-title":"Lugano","year":"2008","author":"Levy","key":"10.1016\/j.hoc.2008.07.013_bib75"},{"key":"10.1016\/j.hoc.2008.07.013_bib76","unstructured":"Favrille announces results from phase 3 registration trial of Specifid in patients with follicular B-cell non-Hodgkin's lymphoma, 2008. Available at: http:\/\/www.favrille.com\/trials\/phase-3-clinical-trial-summary.htm."},{"key":"10.1016\/j.hoc.2008.07.013_bib77","first-page":"647","article-title":"Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma","volume":"110","author":"Ai","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.hoc.2008.07.013_bib78","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1002\/1097-0142(19821215)50:12<2699::AID-CNCR2820501202>3.0.CO;2-A","article-title":"Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute","volume":"50","author":"Anderson","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2008.07.013_bib79","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University","volume":"14","author":"Mac Manus","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib80","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","article-title":"Long-term results with radiotherapy for stage I-II follicular lymphomas","volume":"51","author":"Wilder","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2008.07.013_bib81","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0167-8140(95)01600-L","article-title":"Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma","volume":"36","author":"Pendlebury","year":"1995","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib82","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","article-title":"Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy","volume":"64","author":"Guadagnolo","year":"2006","journal-title":"Int J\u00a0Radiat Oncol Biol Phys"},{"issue":"14S","key":"10.1016\/j.hoc.2008.07.013_bib83","first-page":"653s","article-title":"Long term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone","volume":"22","author":"Peterson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib84","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1200\/JCO.2003.07.111","article-title":"Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma","volume":"21","author":"Seymour","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib85","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijrobp.2007.09.051","article-title":"Impact of [18F] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-Hodgkin lymphoma","volume":"71","author":"Wirth","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2008.07.013_bib86","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib87","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","article-title":"Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab","volume":"23","author":"Horning","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2008.07.013_bib88","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2004-12-4690","article-title":"Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and I131 tositumomab","volume":"105","author":"Bennett","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib89","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.leukres.2006.11.011","article-title":"Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma","volume":"31","author":"Roboz","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2008.07.013_bib90","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/sj.bmt.1704654","article-title":"Stem cell transplantation in follicular lymphoma: progress at last?","volume":"34","author":"Tse","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2008.07.013_bib91","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","article-title":"Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study","volume":"21","author":"Montoto","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2008.07.013_bib92","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib93","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/annonc\/11.suppl_1.S91","article-title":"The CUP trial: a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL)","volume":"11","author":"Schouten","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib94","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib95","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib96","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2004.05194.x","article-title":"Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation","volume":"127","author":"Toze","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2008.07.013_bib97","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood-2002-02-0506","article-title":"The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation","volume":"100","author":"Marks","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib98","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/sj.bmt.1704290","article-title":"Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation","volume":"32","author":"Mandigers","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2008.07.013_bib99","doi-asserted-by":"crossref","first-page":"A44","DOI":"10.1182\/blood.V106.11.44.44","article-title":"Longer follow-up confirms a low relapse rate after non-myeloablative allogeneic transplantation for non-Hodgkin's lymphoma, including patients with PET or gallium-avid disease","volume":"106","author":"Khouri","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib100","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","article-title":"Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality","volume":"98","author":"Khouri","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.013_bib101","first-page":"485","article-title":"Nonmyeloablative allogeneic transplantation (NMT) for relapsed follicular lymphoma (FL): continuous complete remission with longer follow-up","volume":"110","author":"Khouri","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.hoc.2008.07.013_bib102","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib103","first-page":"385","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas\u2014first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)","volume":"110","author":"Rummel","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.hoc.2008.07.013_bib104","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3816\/CLM.2005.n.046","article-title":"Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma","volume":"6","author":"O'Connor","year":"2005","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.hoc.2008.07.013_bib105","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1200\/JCO.2005.09.018","article-title":"Phase I\/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma","volume":"23","author":"Czuczman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib106","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/annonc\/mdm114","article-title":"A phase I\/II study of galiximab (an\u00a0anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma","volume":"18","author":"Leonard","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib107","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","article-title":"Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma","volume":"21","author":"Leonard","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib108","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1200\/JCO.2005.13.821","article-title":"Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.013_bib109","first-page":"2560","article-title":"Results from a phase II study of lenalidomide oral monotherapy in relapsed\/refractory indolent non-Hodgkin's lymphoma","volume":"110","author":"Witzig","year":"2007","journal-title":"ASH Annual Meeting Abstracts"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858808001093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858808001093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:52:12Z","timestamp":1760183532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858808001093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":109,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0889858808001093"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2008.07.013","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Follicular Lymphoma: Clinical Features and Treatment","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2008.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}